Search clinical trials for: recombinant influenza hemagglutinin

Total 3823 results

Protein Sciences Corporation

Completed

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Influenza

United States
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Completed

Recombinant H7 Hemagglutinin Influenza Vaccine Trial (FLU007)

Influenza, Avian

Australia
VaxInnate Corporation

Unknown

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

Influenza

United States
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute; Flinders University

Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults (FLU003)

Influenza

Australia
Protein Sciences Corporation

Completed

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

Influenza

United States
Protein Sciences Corporation

Completed

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Influenza

United States
Protein Sciences Corporation

Completed

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Influenza

United States
Sanofi
Protein Sciences Corporation

Completed

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Influenza

United States
Laboratorios Liomont
EPIC Research CRO; ILS Clinical Research; Q Square Solutions

Completed

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

Influenza, Human

Mexico
VaxInnate Corporation

Unknown

Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

Influenza

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Influenza | Influenza Immunization

United States
VaxInnate Corporation
Department of Health and Human Services; Accelovance

Unknown

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Influenza

United States
The University of Hong Kong
Centers for Disease Control and Prevention

Active, not recruiting

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PIVOT)

Influenza, Human

China
Protein Sciences Corporation

Completed

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PSC26)

Influenza

United States
Vanderbilt University Medical Center

Completed

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Flu Vaccine

United States
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PSC25)

Influenza

United States
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Hong Kong
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
University Hospital, Geneva

Recruiting

Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines (Pertagen2x)

Pertussis | Vaccine-Preventable Diseases

Switzerland
Novavax

Completed

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

Influenza

United States
Henry M. Jackson Foundation for the Advancement...
National Institute of Allergy and Infectious Diseases (NIAID); Food and Drug... and other collaborators

Active, not recruiting

A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED)

Influenza | Influenza-like Illness | Influenza Vaccines

United States
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
UMN Pharma Inc.

Completed

Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults

Influenza

Japan
Marshfield Clinic Research Foundation
Centers for Disease Control and Prevention

Completed

Open-Label Influenza Vaccine Evaluation (OLIVE)

Immune Response

United States
National Institute of Allergy and Infectious Diseases...

Completed

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Influenza | Influenza Immunisation

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine

Influenza

Hungary
Duke University
Boston Medical Center; Centers for Disease Control and Prevention; Children's...

Completed

Safety of RIV4 Versus IIV4 in Pregnant Women

Safety | Birth Outcomes | Adverse Event Following Immunisation

United States
Insight Therapeutics, LLC
Brown University; Sanofi Pasteur, a Sanofi Company; Case Western Reserve University

Active, not recruiting

Recombinant Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza, Human | Influenza -Like Illness

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Influenza (Healthy Volunteers)

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Denmark, Poland, Spain, Czechia
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
Beijing Center for Disease Control and Prevention

Completed

Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine

Healthy

China
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis
Baxalta now part of Shire

Completed

Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A

Hemophilia A

Germany
National Institute of Allergy and Infectious Diseases...

Completed

Flublok or Fluzone With Advax-CpG55.2 or AF03

Influenza | Influenza Immunisation

United States
Duke University
Johns Hopkins University; Centers for Disease Control and Prevention

Completed

Simultaneous RZV and aIIV4 Vaccination

Quality of Life | Pain | Adverse Drug Event | Injection Site Reaction

United States
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

Coronavirus Disease 2019

China
Pfizer

Completed

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Influenza, Human

United States
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1)

Overactive Bladder | Urinary Incontinence

United States, Korea, Republic of, Czechia, Netherlands, Romania, Poland, Turkey, Portugal, Canada, Italy
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

Overactive Bladder | Urinary Incontinence

Spain, Israel, Russian Federation, France, Germany, Australia, Belgium, Brazil, United Kingdom, Mexico, Colombia, Chile, Argentina, Lithuania, Peru, Ukraine
University Hospitals Cleveland Medical Center

Terminated

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

Scar

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany

3

Subscribe